PET Imaging with 62Cu-ETS in a human clinical trial at the university of wisconsin - madison

摘要

Copper(II) bis(thiosemicarbazone) compounds show promise for clinical use in the measurement of tissue blood flow with positron emission tomography (PET). 62Cu-PTSM has been extensively evaluated as a myocardial and general purpose flow agent. Although an effective agent, it exhibits albumin binding in human plasma which limits its performance in high blood flow imaging. A new agent, 62Cu-ETS, exhibits no such species differentiation of albumin binding. In this study, ten healthy human volunteers were subjected to 62Cu-ETS PET imaging to obtain percent injected dose values for major organs, including the blood, brain, kidneys, liver, lungs, and myocardium, by measuring count densities within defined regions of interest (ROI’s) around the general anatomical structure and dividing by the injected dose, correcting for losses at the injection site. These results were then compared to an analogous 62Cu-PTSM PET imaging study completed previously utilizing the same imaging methods. For effective comparison, data for the 62Cu-PTSM study was reanalyzed using the same ROI procedure as was performed on the 62Cu-ETS study. 62Cu-ETS shows similar myocardial uptake compared to 62Cu-PTSM, but kidney uptake is two fold higher than resting myocardium compared with only 1.3 fold for 62Cu-PTSM. Hence 62Cu-ETS shows high promise for the important application of hyperemic myocardial flow measurement as well as renal imaging. An additional advantage of 62Cu-ETS is that liver uptake which can interfere with myocardial imaging is reduced by about 2 fold relative to that of 62Cu-PTSM.